IGC Pharma

We are a clinical stage pharmaceutical company, formerly known as India Globalization Capital, Inc.

About IGC Pharma (dba IGC):

IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing

in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Clinical data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.

08/22/2025

Shaping the Future of Alzheimer’s Care: Our First Quarter in Review

AI-powered tools. Cannabinoid and small molecules platforms. Shaping new ways to understand and address Alzheimer’s disease.

Our dedicated team and partners are committed to delivering progress that brings meaningful value to patients, caregivers, and stakeholders.

08/13/2025

Alzheimer’s disease impacts millions worldwide, yet effective treatment options remain limited. At IGC Pharma, we’re working to change that by advancing therapies that address both the symptoms and the root causes of the disease.

Our pipeline includes IGC-AD1, a proprietary cannabinoid-based therapy in Phase 2 trials, and IGC-M3, a next-generation small molecule in preclinical development. Together, they reflect our commitment to science-driven innovation in Alzheimer’s care.

Beyond the lab, our focus is on transforming promising data into meaningful outcomes for patients, caregivers, and communities affected by neurodegeneration.

At IGC Pharma, we’re redefining what’s possible in Alzheimer's research.

08/11/2025

New preclinical data on IGC-M3 shows promise in the fight against Alzheimer’s

This investigational molecule targets four key drivers of disease progression: amyloid aggregation, oxidative stress, mitochondrial dysfunction, and neuroinflammation in cellular models

These findings reinforce IGC Pharma’s commitment to advancing innovative, potentially disease-modifying therapies that could transform Alzheimer’s care

08/04/2025

Honored to have contributed to AAIC 2025 and advanced Alzheimer’s research

Our AI and scientific teams, along with our CEO and VP, were in Toronto for this year’s Alzheimer’s Association International Conference

We proudly presented three posters showcasing our latest innovations in AI for Alzheimer’s disease:
- MINT-AD: Multimodal Interpretable Transformer for AD
- Early Prediction of MMSE and CSI-D Scores with AI
- AI in the Drug Discovery Pipeline

In addition to sharing our AI work, members of our scientific team also represented the CALMA Clinical Trial, our Phase 2 study investigating IGC-AD1 for agitation in Alzheimer’s

It was a privilege to collaborate with global leaders in dementia research and to contribute to what is next in Alzheimer’s science and care

At IGC Pharma, we remain committed to advancing science that improves lives and to reimagining what is possible in healthcare, together

07/24/2025

IGC Pharma will present 3 scientific posters at the Alzheimer’s Association International Conference 2025, highlighting our artificial intelligence achievements in Alzheimer’s research.

Our presentations explore how AI can support earlier detection, identify high-value clinical opportunities, and streamline drug discovery for underserved and low-resource populations.

Authored by our international research team:

• Poster 108629 – Néstor González, Paola Ruiz, Diego Rodríguez‑Soacha, Daniel Crovo, Ram Mukunda

• Poster 108625 – Paola Ruiz, Néstor González, Daniel Crovo, Catalina Ibañez, Pablo Arbeláez, Ram Mukunda

• Poster 108631 – Daniel Crovo, Paola Ruiz, Néstor González, Pablo Arbeláez, Ram Mukunda

We’re honored to contribute to the world’s largest dementia research forum and to continue advancing innovation in neurodegeneration.

07/22/2025

We’re proud to celebrate the outstanding achievement of Dr. Jagadeesh Rao. He was selected from over 360 nominations across 125 countries. With more than 15 years of contributions to neuroscience, psychiatry, and molecular biology, Dr. Rao continues to shape the future of neurodegenerative research.

His recent work on Alzheimer ’s-related agitation and epigenetic changes in the brain has played a key role in advancing IGC-AD1, IGC’s investigational drug currently in Phase 2 trials. This global recognition reinforces IGC Pharma’s commitment to pioneering science-backed therapeutics for Alzheimer’s disease.

Read more: https://igcpharma.com/igc-pharmas-principal-scientist-dr-jagadeesh-rao-receives-best-researcher-award-at-11th-annual-world-neuroscience-awards/

07/11/2025

A Breakthrough Moment from IGC Pharma: Powered by AI

We’re proud to introduce MINT-AD, our proprietary AI platform designed to identify individuals at high risk of Alzheimer’s years before symptoms appear. Built on multimodal data, including brain scans, genomics, and lifestyle, MINT-AD is designed for scale and personalized diagnostics to support earlier detection and precision care.

Read more: https://investor.igcpharma.com/igc-pharma-introduces-mint-ad-proprietary-ai-platform-to-predict-alzheimers-risk/

, , , , , , , ,

07/01/2025

IGC Pharma hosted its Fiscal Year-End 2025 Shareholder Update Call yesterday, covering key milestones from the past year and our outlook for the CALMA Trial, AI platform, and pipeline expansion.

Replay available here: https://www.webcaster4.com/Webcast/Page/2938/52547

, , , , , ,

06/30/2025

Save the date! IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on June 30 at 11:00 am ET. We invite investors and stakeholders to join us for a business update and live Q&A with management.

Read the full press release: https://investor.igcpharma.com/igc-pharma-fiscal-year-2025/

Dial-in or stream live: https://www.webcaster4.com/Webcast/Page/2938/52547

06/27/2025

📣 Join the IGC Pharma Webcast

We invite you to join our upcoming webcast, where we’ll provide updates on IGC Pharma’s latest clinical developments, research initiatives, and strategic priorities.

This is a valuable opportunity to hear directly from our leadership team about our progress in Alzheimer’s research and innovation in neurodegenerative disease treatment.

Focused on advancing care through clinical trials, AI-powered drug development, and patient-centered research.

Join the webcast
https://www.webcaster4.com/Webcast/Page/2938/52547

🗓 Date: Monday, June 30, 2025
🕚 Time: 11:00 A.M. Eastern Time
Replay available through: September 30, 2025

Dial-in numbers:
- US: (888) 506 0062
- International: (973) 528 0011
Access Code: 370284

Driving innovation in healthcare, together

06/26/2025

Meet Our Summer Navigators

We’re thrilled to welcome our incredible cohort of Summer Interns—students and graduates in Chemistry, Biology, and Pre-Pharmacy—who are bringing curiosity, dedication, and a passion for science to IGC Pharma this summer. 🔬

Over the past month, our Navigators have been actively involved in patient recruitment and have completed Good Clinical Practice (GCP) certification. Through this internship, they’re gaining exposure to clinical trials, drug development, and the research that drives progress in healthcare.

We’re proud to support this next generation of researchers as they continue their journey into science, medicine, and innovation. 🧪

Say hello to:
Timag Sherif
Meti Abdella
Kiersten N. Chaney
Alexander Antram
Shaimaa Hammett

Let’s build the future of healthcare, together.

06/24/2025

We’re proud to announce the expansion of our Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation in Alzheimer’s dementia, with a new site opening at Tekton Research in Yukon, Oklahoma. This strategic addition reflects IGC Pharma’s commitment to addressing regional healthcare disparities and enhancing diversity across our clinical studies.

Led by Dr. David McCoy, a board-certified neurologist and native Oklahoman, the Yukon site brings deep expertise in Alzheimer’s research and strengthens our ability to reach underrepresented populations.

This milestone also underscores our broader mission: to combine advanced clinical research with AI-powered innovation—to accelerate drug discovery, optimize clinical trials, and improve patient targeting in the fight against neurodegenerative diseases.

Address

Potomac, MD

Telephone

+13019830998

Website

https://igcpharma.com/

Alerts

Be the first to know and let us send you an email when IGC Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.